Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Trospium Chloride Clear all
Recruiting Phase 3 Interventional

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
147
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline tartrate, Trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

NCT03109379
View directory record Official record
Conditions
Idiopathic Overactive Bladder With Urinary Incontinence
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Pompano Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

NCT00932022
View directory record Official record
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

NCT05643170
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Anticholinergics on Cognitive Function in the Elderly

NCT01922115
View directory record Official record
Conditions
Mental Competency, Urinary Bladder, Overactive, Cognitive Function
Interventions
Trospium Chloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 99 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

NCT04227184
View directory record Official record
Conditions
Urgency Urinary Incontinence
Interventions
Trospium, Placebo oral tablet
Drug
Lead sponsor
Becky Clarkson
Other
Eligibility
60 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

NCT06947941
View directory record Official record
Conditions
Alzheimer Disease, Psychosis
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Gilbert, Arizona • Chino, California • Naples, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting No phase listed Observational

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

NCT07101094
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline and trospium chloride (X/T) therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Costa Mesa, California • San Jose, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

NCT03168828
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Troy, Michigan • Charlotte, North Carolina • Virginia Beach, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

NCT07681076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Trimethobenzamide, Ondansetron, Meclizine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 26, 2026, 10:37 AM EDT
Recruiting No phase listed Observational

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

NCT07379827
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and trospium chloride (KarXT)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
55
States / cities
Bryant, Arkansas • Anaheim, California • Chino, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

NCT04738123
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 26, 2026, 10:37 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia

NCT07783373
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline-trospium chloride, Oral antipsychotics
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Suwanee, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Not yet recruiting Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

NCT06923891
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/Trospium
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

NCT00465959
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
trospium chloride inhalation powder (TrIP), Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 26, 2026, 10:37 AM EDT